Elevated plasma levels of adropin in heart failure patients

Internal Medicine

Volumn 50, Issue 15, 2011, Pages 1523-1527

  Lian, Wenlin ^a   Gu, Xiaosong ^a   Qin, Yongwen ^a   Zheng, Xing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adropin; Brain natriuretic peptide; Heart failure

Indexed keywords

ADROPIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ADROPIN BLOOD LEVEL; ADULT; AGED; ARTICLE; BODY MASS; BRAIN NATRIURETIC PEPTIDE BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FUNCTIONAL STATUS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; BLOOD PROTEINS; CASE-CONTROL STUDIES; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROTEINS; REGRESSION ANALYSIS; ROC CURVE;

EID: 79961174135     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.5163     Document Type: Article

References (16)

1. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 347: 305-313, 2002.
2. Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 91: 891-894, 2003.
3. Horwich TB, Fonarow GC. The impact of obesity on survival in patients with heart failure. Heart Fail Monit 3: 8-14, 2002.
4. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 43: 1590-1595, 2004.
5. Davos CH, Doehner W, Rauchhaus M, et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail 91: 29-35, 2003.
6. Poehlman ET, Scheffers J, Gottlieb SS, Fisher ML, Vaitekevicius P. Increased resting metabolic rate in patients with congestive heart failure. Ann Intern Med 121: 860-862, 1994.
7. Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 8: 468-481, 2008.
8. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96: 509-516, 1997.
9. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109: 594-600, 2004.
10. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87: 1402-1412, 1991.
11. Lovren F, Pan Y, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation 122 (11 Suppl): S185-S192, 2010.
12. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 84: 1589-1596, 1991.
13. Kasprzak JD, Klosinska M, Drozdz J. Clinical aspects of assessment of endothelial function. Pharmacol Rep 58 (Suppl): 33-40, 2006.
14. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91: 1314-1319, 1995.
15. Lafontan M, Berlan M, Stich V, et al. Recent data on the regulation of lipolysis by catecholamines and natriuretic peptides. Ann Endocrinol (Paris) 63 (2 Pt 1): 86-90, 2002.
16. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349: 1050-1053, 1997.